Clinical trials: Horton Disease
Adrenal Insufficiency, Polymyalgia Rheumatica (PMR)
Hydrocortisone and Placebo in Patients With Symptoms of Adrenal Insufficiency After Cessation of Glucocorticoid Treatment
Cortisol, a glucocorticoid (GC) hormone secreted from the adrenal glands, is essential for survival. Cortisol also possesses anti-inflammatory actions and GC formulations (prednisolone) are used to treat many inflammatory…
- Conditions
- Adrenal Insufficiency, Polymyalgia Rheumatica (PMR), Giant Cell Arteritis (GCA)
- Trial name
- REPLACE (NCT05193396)
- Testing
- Hydrocortisone
- Where
- 3 sites in Denmark
- Volunteers
- 100 people
- Sponsor
- Marianne Andersen
Horton's Disease, Infectious Disease
Quantitative and Functional Study of TH17 Lymphocytes in Horton's Disease (HD)
The aim of this open, controlled, multicentre biomedical research study is to identify new markers specifically associated with Horton's disease.
- Conditions
- Horton's Disease, Infectious Disease, Neoplasia, Solid Tumor
- Trial name
- NCT02065297
- Testing
- 1 blood sample, 2 to 3 blood samples (at inclusion, at 3 months and at 6 months in cases of relapse)
- Where
- 3 sites in France
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Dijon
Giant Cell Arteritis
KPL-301 for Subjects With Giant Cell Arteritis
The primary objective of the study is to evaluate the efficacy of mavrilimumab (KPL-301) versus placebo, co-administered with a 26-week corticosteroid taper, for maintaining sustained remission for 26 weeks in subjects with new…
- Trial name
- NCT03827018
- Testing
- mavrilimumab, prednisone
- Where
- 49 sites in United States, Australia and 13 more
- Volunteers
- 70 people
- Sponsor
- Kiniksa Pharmaceuticals, Ltd.
Polymyalgia Rheumatica
Infliximab Therapy in Patients With Refractory Polymyalgia Rheumatica
Rheumatic Polymyalgia(PMR) is a relatively common chronic inflammatory disorder of unknown origin which predominantly develops in elderly subjects and presents with severe pain and stiffness in the neck, shoulder and pelvic…
- Trial name
- NCT01423591
- Testing
- infliximab, inactive powder
- Where
- Spain
- Volunteers
- 23 people
- Sponsor
- Hospital Universitario Marqués de Valdecilla
Giant Cell Arteritis, Vasculitis
Giant Cell Arteritis and Differential Diagnoses Associated With Positive Temporal Artery Biopsy
Temporal artery biopsy is a useful tool helping to the diagnosis of giant cell arteritis. However, other diagnoses might be associated with abnormal temporal artery biopsy.
- Trial name
- NCT04554290
- Testing
- temporal artery biopsy
- Where
- France
- Volunteers
- 114 people
- Sponsor
- Central Hospital, Nancy, France
Giant Cell Arteritis
A Clinical Trial to Investigate 18F-AzaFol in the Diagnosis of Large Vessel Vasculitis
The goal of this open-label clinical trial is to evaluate the efficacy of AzaFol-PET/CT in the diagnosis of GCA (giant cell arteritis), to compare AzaFol- with 2-[18F]FDG-PET/CT, and to assess the safety and tolerability of…
- Trial name
- CRAFT (NCT06335888)
- Testing
- AzaFol, FDG
- Where
- Switzerland
- Volunteers
- 70 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Giant Cell Arteritis
Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA
Primary Objective: To evaluate the efficacy of sarilumab in participants with giant cell arteritis (GCA) as assessed by the proportion of participants with sustained remission for sarilumab compared to placebo, in combination…
- Trial name
- NCT03600805
- Testing
- Sarilumab SAR153191, Prednisone
- Where
- 61 sites in United States, Argentina and 19 more
- Volunteers
- 83 people
- Sponsor
- Sanofi
Polymyalgia Rheumatica
Validation of the PMR Activity Score and Evolution of Patient-reported Outcomes in Patients With Polymyalgia Rheumatica
Polymyalgia rheumatica (PMR) is a systemic inflammatory disease that affects elderly people. It is characterized by pain and morning stiffness in the shoulders, pelvic girdles and neck.
- Trial name
- NCT05542316
- Where
- Belgium
- Volunteers
- 133 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Polymyalgia Rheumatica, Giant Cell Arteritis
Polymyalgia Rheumatica and Giant Cell Arteritis
The purpose of this study is to delineate the association of the 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (18F-FDG PET/CT) detected vasculitis pattern of the large vessels (PET positivity) and the…
- Trial name
- NCT02985424
- Testing
- 18F-FDG PET/CT
- Where
- Denmark
- Volunteers
- 80 people
- Sponsor
- Svendborg Hospital
Giant Cell Arteritis
Prospective Follow-up Study of the Aortic Diameter in Patients With Giant Cell Arteritis
Giant cell arteritis (GCA) is the most frequent vasculitis in patients above 50 years of age. The disease has limited mortality, mostly due to the development of aortic aneurysms, leading to dissection and rupture.
- Trial name
- ATACT (NCT01588483)
- Where
- Belgium
- Volunteers
- 163 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Rheumatic Diseases, Adult Onset Still Disease
Rheumatology Patient Registry and Biorepository
To facilitate clinical, basic science, and translational research projects involving the study of rheumatic diseases.
- Conditions
- Rheumatic Diseases, Adult Onset Still Disease, Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- NCT04402086
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Yale University
Giant Cell Arteritis
Temporal Artery Biopsy vs ULtrasound in Diagnosis of GCA (TABUL)
Giant Cell Arteritis (GCA) causes inflammation and narrowing of blood vessels and can cause blindness in one third of patients. It is important that a prompt, accurate diagnosis of GCA is made and treatment given as steroids for…
- Trial name
- TABUL (NCT00974883)
- Testing
- Ultrasound of temporal and axillary arteries, Temporal artery biopsy
- Where
- 27 sites in Germany, Ireland and 3 more
- Volunteers
- 880 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Giant Cell Arteritis, Temporal Arteritis
Ustekinumab for the Treatment of Giant Cell Arteritis
The purpose of this study is to determine whether ustekinumab is effective in the treatment of Giant Cell Arteritis (GCA)
- Conditions
- Giant Cell Arteritis, Temporal Arteritis, Horton's Disease
- Trial name
- UGCA (NCT02955147)
- Testing
- Ustekinumab, Prednisone
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Massachusetts General Hospital
Aortitis, Giant Cell Arteritis (GCA)
TocILizumab in aorTitis in GCA (TILT)
This is a french multicenter observational study assessing safety and efficacy of biosimilar of Tocilizumab in Giant Cell Arteritis (GCA) with active aortitis, including 14 reference centers from the Groupe d'Etude Français des…
- Trial name
- TILT (NCT06271018)
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Groupe français d'étude des Maladies Inflammatoires de loeil
Giant Cell Arteritis, Large Vessel Giant Cell Arteriitis
Longitudinal Imaging in Patients With Large Vessel Vasculitis to Predict Further Disease Course
Longitudinal imaging in patients with large vessel vasculitis to predict further disease course
- Trial name
- NCT04204876
- Testing
- Magnet Resonance Imaging (MRI), PET/CT analysis
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- University Hospital, Basel, Switzerland
Wegener Granulomatosis, Microscopic Polyangiitis
Vasculitis Illness Perception (VIP) Study
The purpose of this study is to learn about how patients with vasculitis think about their illness and to assess to what extent patient perceptions of illness are associated with physical, mental, and social functioning
- Conditions
- Wegener Granulomatosis, Microscopic Polyangiitis, Churg-Strauss Syndrome, Polyarteritis Nodosa
- Trial name
- NCT02190916
- Where
- United States
- Volunteers
- 707 people
- Sponsor
- University of South Florida
Giant Cell Arteritis
Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Giant Cell Arteritis: Proof of Concept Study.
It has been reported that around 40% of GCA patients are able to decrease the prednisone dose until 0.1 mg/Kg/d or less after 6 months of treatment.
- Trial name
- HORTOCI (NCT01910038)
- Testing
- corticoids+ tocilizumab 8mg/Kg/4 weeks
- Where
- 8 sites in France
- Volunteers
- 20 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Giant Cell Arteritis
TocilizuMab discontinuAtion in GIant Cell Arteritis
Giant cell arteritis (GCA) is a large-vessel vasculitis that typically occurs in people over the age of 50. Corticosteroids (GC) are the cornerstone of treatment for GCA.
- Trial name
- MAGICA (NCT06037460)
- Testing
- Tocilizumab treatment, questionnaires, Blood samples
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Giant Cell Arteritis
HECTHOR: Humira to Spare Steroids in Giant Cell Arteritis
Hypothesis: In giant cell arteritis (GCA), a short initial treatment with anti-TNF may allow a faster decrease of steroids dosage and therefore avoid some of the adverse events of steroids.
- Trial name
- NCT00305539
- Testing
- adalimumab
- Where
- France
- Volunteers
- 69 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Giant Cell Arteritis
Diagnostic Accuracy of FDG PET/CT of Cranial Arteries in GCA
A case-control study to evaluate the diagnostic accuracy of FDG uptake in cranial arteries by FDG PET/CT in the diagnosis of giant cell arteritis.
- Trial name
- NCT03409913
- Testing
- FDG PET/CT
- Where
- Denmark
- Volunteers
- 106 people
- Sponsor
- University of Aarhus